Literature DB >> 9367266

Estrogen decreases corpus striatal neurotoxicity in response to 6-hydroxydopamine.

D Dluzen1.   

Abstract

Ovariectomized rats treated or not with an estradiol pellet were subjected to an unilateral intrastriatal infusion of 6-hydroxydopamine (6-OHDA). Various parameters of nigrostriatal dopaminergic function as derived from measurements of dopamine and dihydroxyphenylacetic acid (DOPAC) concentrations were determined from the 6-OHDA lesioned and non-lesioned sides of the corpus striatum in these animals. Dopamine concentrations within the 6-OHDA lesioned striatum of estrogen-treated rats were significantly greater than non-estrogen-treated rats. There were no differences in striatal dopamine concentrations between estrogen- versus non-estrogen-treated rats on their non-lesioned side. In contrast to that of dopamine, no differences in DOPAC concentrations between estrogen and non-estrogen-treated rats were obtained within the 6-OHDA-lesioned side. The DOPAC concentrations on the non-lesioned side of the striatum were significantly greater in the non-estrogen-treated rats. These results demonstrate that estrogen significantly diminishes the depletion of striatal dopamine resulting from the neurotoxin 6-OHDA. The data obtained from the DOPAC determinations imply that this capacity of estrogen may be exerted through actions upon uptake processes of striatal dopaminergic neurons. Such findings suggest that estrogen may function as an important modulatory factor capable of attenuating degeneration within the corpus striatum, and in this way serve as a neuroprotectant of the nigrostriatal dopaminergic system.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9367266     DOI: 10.1016/s0006-8993(97)00630-6

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  27 in total

1.  The antioxidant neuroprotective effects of estrogens and phenolic compounds are independent from their estrogenic properties.

Authors:  B Moosmann; C Behl
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

Review 2.  Estrogen as neuroprotectant of nigrostriatal dopaminergic system: laboratory and clinical studies.

Authors:  Dean Dluzen; Martin Horstink
Journal:  Endocrine       Date:  2003-06       Impact factor: 3.633

3.  Risk factors for Parkinson's disease may differ in men and women: an exploratory study.

Authors:  Rodolfo Savica; Brandon R Grossardt; James H Bower; J Eric Ahlskog; Walter A Rocca
Journal:  Horm Behav       Date:  2012-06-08       Impact factor: 3.587

4.  Effects of age, gender, and gonadectomy on neurochemistry and behavior in animal models of Parkinson's disease.

Authors:  Andrea Tamás; Andrea Lubics; István Lengvári; Dóra Reglodi
Journal:  Endocrine       Date:  2006-04       Impact factor: 3.633

5.  Estradiol promotes proliferation of dopaminergic precursors resulting in a higher proportion of dopamine neurons derived from mouse embryonic stem cells.

Authors:  Néstor F Díaz; Néstor E Díaz-Martínez; Ignacio Camacho-Arroyo; Iván Velasco
Journal:  Int J Dev Neurosci       Date:  2009-04-18       Impact factor: 2.457

6.  Effect of different doses of estrogen on the nigrostriatal dopaminergic system in two 6-hydroxydopamine-induced lesion models of Parkinson's disease.

Authors:  Marcela Ferreira Cordellini; Giovana Piazzetta; Karin Cristine Pinto; Ana Márcia Delattre; Francesca Matheussi; Ruither O G Carolino; Raphael Escorsim Szawka; Janete A Anselmo-Franci; Anete Curte Ferraz
Journal:  Neurochem Res       Date:  2011-02-24       Impact factor: 3.996

7.  Ovariectomy of adult rats leads to increased expression of astrocytic basic fibroblast growth factor in the ventral tegmental area and in dopaminergic projection regions of the entorhinal and prefrontal cortex.

Authors:  C Flores; N Salmaso; S Cain; D Rodaros; J Stewart
Journal:  J Neurosci       Date:  1999-10-01       Impact factor: 6.167

8.  Tamoxifen eliminates estrogen's neuroprotective effect upon MPTP-induced neurotoxicity of the nigrostriatal dopaminergic system.

Authors:  D E Dluzen; J L McDermott; L I Anderson
Journal:  Neurotox Res       Date:  2001-07       Impact factor: 3.911

9.  Changes in the content of estrogen alpha and progesterone receptors during differentiation of mouse embryonic stem cells to dopamine neurons.

Authors:  Néstor F Díaz; Christian Guerra-Arraiza; Néstor E Díaz-Martínez; Patricia Salazar; Anayansi Molina-Hernández; Ignacio Camacho-Arroyo; Ivan Velasco
Journal:  Brain Res Bull       Date:  2007-02-28       Impact factor: 4.077

10.  PI3 kinase/Akt activation mediates estrogen and IGF-1 nigral DA neuronal neuroprotection against a unilateral rat model of Parkinson's disease.

Authors:  Arnulfo Quesada; Becky Y Lee; Paul E Micevych
Journal:  Dev Neurobiol       Date:  2008-04       Impact factor: 3.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.